Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Marksans Pharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Marksans Pharma hat ein Gesamteigenkapital von ₹19.0B und eine Gesamtverschuldung von ₹1.1B, wodurch sich der Verschuldungsgrad auf 5.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹23.1B bzw. ₹4.2B. Marksans Pharma Das EBIT des Unternehmens beträgt ₹3.9B, so dass der Zinsdeckungsgrad -62.5 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹6.6B.

Wichtige Informationen

1.4%

Verhältnis von Schulden zu Eigenkapital

₹290.91m

Verschuldung

Zinsdeckungsgrad	38.8x
Bargeld	₹7.01b
Eigenkapital	₹20.86b
Gesamtverbindlichkeiten	₹5.95b
Gesamtvermögen	₹26.81b

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Nov 19

Recent updates

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Nov 19

Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Nov 04

If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late

Oct 20

Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?

Oct 05

If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns

Sep 20

A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)

Aug 20

Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)

Aug 05

If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late

Jul 08

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: MARKSANSDie kurzfristigen Aktiva des Unternehmens (₹17.0B) übersteigen seine kurzfristigen Passiva (₹3.3B).

Langfristige Verbindlichkeiten: MARKSANSDie kurzfristigen Vermögenswerte des Unternehmens (₹17.0B) übersteigen seine langfristigen Verbindlichkeiten (₹838.2M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: MARKSANS über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: MARKSANS Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 21.3% auf 5.9% zurückgegangen.

Schuldendeckung: MARKSANSDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (227.6%).

Zinsdeckung: Die Zinszahlungen für die Schulden von MARKSANS sind durch das EBIT gut gedeckt (38.8x coverage).

Marksans Pharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Recent updates

Full year 2024 earnings: EPS misses analyst expectations

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24

Marksans Pharma Limited to Report Q4, 2024 Results on May 30, 2024

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023)

Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets

Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹6.39 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Investor sentiment improves as stock rises 16%

Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg

Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023

Full year 2023 earnings released: EPS: ₹6.41 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.20 in 3Q 2022)

Marksans Pharma Limited to Report Q3, 2023 Results on Feb 13, 2023

Marksans Pharma Limited announced that it has received funding from OrbiMed Asia IV Mauritius FVCI Limited

Second quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.11 in 2Q 2022)

Marksans Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022

Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited.

Marksans Pharma Limited Declares Dividend, Payable on or After 20 September 2022

Upcoming dividend of ₹0.25 per share

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹5.83 in FY 2021)

Marksans Pharma Limited to Report Q1, 2023 Results on Aug 13, 2022

Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022

Marksans Pharma Limited Announces US FDA Approval for Pregabalin Capsules

Marksans Pharma Limited (BSE:524404) announces an Equity Buyback for INR 600 million worth of its shares.

Investor sentiment improved over the past week

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Marksans Pharma Limited (BSE:524404) completed the acquisition of Access Healthcare for Medical Products LLC.

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Fiscal Year 2022 Results on May 30, 2022

Marksans Pharma Limited (BSE:524404) has signed agreement to acquire share capital of Access Healthcare for Medical Products LLC for AED 13 million.

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Q3, 2022 Results on Feb 11, 2022

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Second quarter 2022 earnings released: EPS ₹1.11 (vs ₹1.21 in 2Q 2021)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Upcoming dividend of ₹0.25 per share

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

First quarter 2022 earnings released: EPS ₹1.51 (vs ₹1.20 in 1Q 2021)

Investor sentiment deteriorated over the past week

Marksans Pharma Limited announced that it has received INR 930.999994 million in funding from OrbiMed Asia IV Mauritius FVCI Limited and other investor

Marksans Pharma Limited announced that it expects to receive INR 930.999994 million in funding

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹5.76 (vs ₹2.95 in FY 2020)

Marksans Pharma Limited Recommends Dividend for the Financial Year Ended March 31, 2021

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Investor sentiment improved over the past week

New 90-day low: ₹54.00

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Third quarter 2021 earnings released: EPS ₹1.42 (vs ₹0.71 in 3Q 2020)

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Marksans Pharma Limited to Report Q3, 2021 Results on Feb 08, 2021

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?